Viridian Therapeutics (VRDN) to Release Quarterly Earnings on Tuesday

Viridian Therapeutics (NASDAQ:VRDN) is projected to issue its quarterly earnings data before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($1.05) per share and revenue of $0.05 million for the quarter.

Viridian Therapeutics Stock Down 2.1 %

VRDN opened at $16.27 on Monday. The firm has a 50-day simple moving average of $18.63 and a two-hundred day simple moving average of $19.68. Viridian Therapeutics has a 52 week low of $11.40 and a 52 week high of $27.20. The company has a market capitalization of $1.29 billion, a PE ratio of -3.77 and a beta of 1.32. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04.

Analyst Ratings Changes

A number of research analysts recently commented on VRDN shares. TD Cowen started coverage on shares of Viridian Therapeutics in a report on Monday, November 25th. They issued a “buy” rating for the company. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $27.00 price target (down previously from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Royal Bank of Canada increased their price target on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a report on Tuesday, December 17th. Needham & Company LLC reissued a “buy” rating and issued a $38.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research note on Monday, December 16th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, Viridian Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.70.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.